J&J Sees Growth Opportunities Through Partnerships And Emerging Markets After Facing Early Patent Cliff

Johnson & Johnson is increasingly looking to partnerships as part of its strategy to bounce back from the onset of generic competition for its mega drugs Risperdal Oral (risperidone) and Topamax (topiramate)